Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MOMICS biomarker prediction study for antihypertensive response
NL-OMON58963Phase 4Active, not recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of olmesartan, amlodipine and hydrochlorothiazide in essential hypertension (4 arms), sponsored by Radboud University Medical Center. Primary endpoint: Prediction of 24-hour blood pressure response. Started Mar 2024; status: active, not recruiting.
02
Drugs
olmesartanamlodipinehydrochlorothiazide
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NL-OMON58963.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58963.